Treatment of dysfunctional uterine bleeding in the perimenopause: the effects of adding combined estradiol/norethisterone acetate therapy to goserelin acetate treatment--a randomized, placebo-controlled, double-blind trial.
OBJECTIVE
To assess the effects of adding combined estradiol/norethisterone acetate therapy (CENT) to goserelin acetate treatment (GA) of dysfunctional uterine bleeding (DUB) in perimenopausal women.


METHODS
In a randomized, placebo-controlled, double-blind trial followed by an open follow-up study, 31 perimenopausal women with DUB were recruited from gynecological outpatient departments of two Dutch hospitals and randomized for treatment with either GA/placebo or GA/CENT for 6 months followed by 18 months of GA/CENT for all. The main outcome measures were abdominal pain, number of bleeding days, double-layer endometrial thickness (DET), Greene climacteric score (GCS), visual analog scale for well-being, bone mineral density (BMD) and mammographic density (BI-RAD score).


RESULTS
Abdominal pain, number of bleeding days and DET decreased in both groups, the between-group difference in decrease not being statistically significant. GCS initially showed significant improvement in the GA/CENT group. BMD decreased significantly in the GA/placebo group (-4.1%) compared with the GA/CENT group (-0.3%). Another 18 months of GA/CENT did not result in a lasting difference in BMD between groups. BI-RAD scores did not differ significantly between or within the two groups.


CONCLUSIONS
Adding CENT to GA treatment for DUB in perimenopausal women initially prevented BMD loss and improved climacteric complaints, while having no negative impact on vaginal bleeding, abdominal pain or BI-RAD scores. However, prolonged treatment did not result in a lasting prevention of bone loss.
Franke
Henk R
HR
Department of Obstetrics and Gynecology, Medisch Spectrum Twente Hospital Group, Enschede, The Netherlands.
Snaaijer
F Froukje
FF
Houben
Paul W H
PW
van der Mooren
Marius J
MJ
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D015519:Bone Density / Q000187:drug effects; D002979:Climacteric / Q000187:drug effects / Q000502:physiology; D004311:Double-Blind Method; D004338:Drug Combinations; D004958:Estradiol / Q000627:therapeutic use*; D005260:Female; D017273:Goserelin / Q000627:therapeutic use*; D020249:Hormone Replacement Therapy; D006801:Humans; D008327:Mammography; D008796:Metrorrhagia / Q000188:drug therapy*; D008875:Middle Aged; D009640:Norethindrone / Q000627:therapeutic use*; D047648:Perimenopause / Q000187:drug effects
D018931:Antineoplastic Agents, Hormonal; D004338:Drug Combinations; D017273:Goserelin; D004958:Estradiol; D009640:Norethindrone